Pharmaceutical manufacturers in Canada often enter into Product Listing Agreements (PLA), particularly with public payors, to facilitate their drug being reimbursed. It is common for PLAs to take the form of a first dollar...more
On November 23, 2020, Innovative Medicines Canada (IMC) and a number of research-based pharmaceutical companies commenced an application for judicial review (T-1419-20) of the final Patented Medicine Prices Review Board...more
Innovative Medicines Canada (IMC) has announced changes to its Code of Ethical Practices for the first time since the last significant update in 2014. IMC has indicated that several major changes have been made which include...more